Business
EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
MILAN & MORRISTOWN, N.J., January 07, 2026--Newron's partner EA Pharma Co., Ltd. announces today the initiation of its Phase III clinical trial with evenamide in Japan.
About this update from Eisai Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":281,"url":"https://media.zenfs.com/en/business-wire.com/691756091b10656b27477e459779d14b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QcW.XmaWM2VqYnOCLVxVUQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/691756091b10656b27477e459779d14b","width":480,"height":281}},"lazy":false},{"type":"text","content":"MILAN & MORRISTOWN, N.J., January 07, 2026--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, is pleased to note that its partner EA Pharma Co., Ltd. (EAP), has announced today the initiation of its Phase III clinical trial with evenamide, a novel excessive glutamate release modulator, in Japan.","length":490,"tagName":"p"},{"type":"text","content":"Stefan Weber, CEO of Newron Pharmaceuticals, commented: "The initiation of EA Pharma’s Phase III study of evenamide in Japan represents an important step in the global development of the program. This milestone, together with Newron’s ongoing global (excluding EAP territories) ENIGMA-TRS Phase III studies reflects continued progress and momentum for evenamide and further supports its potential as a differentiated add-on therapy in schizophrenia."","length":460,"tagName":"p"},{"type":"text","content":"The full text of the announcement from EAP is as follows:","length":57,"tagName":"p"},{"type":"text","content":"EA Pharma Announces Initiation of Phase III Clinical Trial of EA8001, a Novel Treatment for Schizophrenia, in Japan","length":115,"tagName":"p","attribs":{}},{"type":"text","content":"EA Pharma Co., Ltd. (Head Office, Chuo-ku, Tokyo, Japan; President, Hidenori Yabune; "EA Pharma") announced today that Phase III clinical trial of EA8001 (non -proprietary name: evenamide), a novel excessive glutamate release modulator, is now ready to begin in Japan (hereinafter the "Trial").","length":314,"tagName":"p"},{"type":"text","content":"EA Pharma initiates the Trial after review by the institutional review board of the clinical site and other related procedures. This Tri...